Carrie A Thompson MD MS

Hematologic Oncology

Professor, Internal Medicine, Mayo Medical School

200 1st Street SWRochester, MN 55905

Dr. Thompson is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Thompson's full profile Already have an account?

Summary

Dr. Carrie Thompson is a hematology specialist located in Rochester, MN, with subspecialty expertise in hematologic oncology, particularly follicular lymphoma and lymphoma. She completed her medical education at Saint Louis University School of Medicine in 2001, followed by a residency in internal medicine and a fellowship in hematology and medical oncology at the Mayo Clinic. She has been an Associate Consultant at the Mayo Clinic since 2007. Dr. Thompson's recent publications focus on patient-reported outcomes, marginal zone lymphoma, and survivorship care guidelines for lymphoma. She has received numerous honors, including the Program Director Recognition Award from the Mayo Clinic in 2024 and an Outstanding Hematology Trainee award.

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2004 - 2007
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2001 - 2004
Saint Louis University School of MedicineClass of 2001
Saint Louis UniversityB.S., Biology, Magna Cum Laude, 1993 - 1997

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MN State Medical License 2002 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Program Director Recognition Award Mayo Clinic School of Graduate Medical Education, 2024
CMS Meaningful Use Stage 1 Certification Centricity Enterprise, GE Healthcare, 2013-2017
CMS Meaningful Use Stage 1 Certification Centricity Enterprise, GE Healthcare, 2013-2017

Publications & Presentations

PubMed

Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.
George A Cholack, Raphael Mwangi, Prokop Vodička, Thomas M Habermann, Verena Hinder
British Journal of Haematology. 2026-05-01
1 citations
Use of a Cystatin C-Based GFR Equation in a Population Pharmacokinetic Model of Methotrexate Clearance in Adult Patients with Lymphoma.
Zachary L Taylor, Erin F Barreto, Kristin C Cole, Andrew D Rule, Kianoush B Kashani
Clinical Pharmacokinetics. 2026-03-01
Occurrence and predictors of patient reported fertility discussions in non-Hodgkin lymphoma patients: utilizing the lymphoma epidemiology of outcomes (LEO) cohort study.
Nadia Toumeh, Melissa Larson, Brianna Negaard, Carla Casulo, Sairah Ahmed
Leukemia & Lymphoma. 2026-01-01

Journal Articles

Diagnostic utility of FDG-PET in neurolymphomatosis
Toledano M, Siddiqui MA, Thompson CA, Garza I, Pittock SJ, Neurology, 1/1/2013
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas
Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF, Johnston PB, Colgan JP, Markovic SN, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Gupta..., Blood, 1/3/2011
Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors
Thompson CA, Charlson ME, Schenkein E, Wells MT, Furman RR, Elstrom R, Ruan J, Martin P, Leonard JP, Ann Oncol, 1/1/2010

Books/Book Chapters

Mayo Clinic internal medicine board review.
Chapter: Malignant hematology.
Page 528 - 538Thompson CAEditors: Ficalora RD; et al.Mayo Clinic Scientific Press, Rochester, MNEdition 10th,2013

Abstracts/Posters

A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...
Carrie A. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of Preemptive Leucovorin Dose Escalation on Incidence of Delayed Methotrexate Elimination in Lymphoma Patients Receiving High-Dose Methotrexate
Carrie A. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life
Carrie A. Thompson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Embarrassment of Riches: Storing, Managing, and Interpreting the Vast Data Produced by These...
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Patient-reported outcomes, emoji, and activity measured on the Apple Watch in cancer patients.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Other

Burkitt Lymphoma.
Thompson CA, AskMayoExpert
http://javaprod.mayo.edu/ame/openTopic?collection=1&topicID=4431
1/14/2013

Press Mentions

Jonathan Friedberg: PROs vs Clinician-Reported Adverse Events in a Large Clinical TrialSeptember 29th, 2025
Pushing the Limits of Gene TherapyNovember 19th, 2021
Helping Others Heal: Monitoring Cancer Patients’ Health Through EmojisApril 30th, 2019